Bavarian Nordic A/S (LON:0DPB)

Market Cap	1.50B
Revenue (ttm)	677.30M
Net Income (ttm)	124.82M
Shares Out	n/a
EPS (ttm)	1.59
PE Ratio	12.04
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,199
Average Volume	16,521
Open	174.35
Previous Close	172.99
Day's Range	170.60 - 175.00
52-Week Range	15.94 - 32.81
Beta	1.64
RSI	38.47
Earnings Date	Mar 5, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,379
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DPB

Financial Performance

Financial numbers in DKK